ABS & Biocultural Rights Governance
Organisations focused on access and benefit-sharing, biocultural preservation, and equitable frameworks for psychedelic development.
When a company develops a medicine from a plant that Indigenous communities have used for generations, who owes what to whom? ABS (access and benefit-sharing) is the governance framework built to answer that, anchored in the Nagoya Protocol, and this category tracks the institutions that make it work: compliance and monitoring bodies, national focal points, traceability auditors, ethical-trade organisations, and biocultural preservation groups.
Psychedelics make the question urgent rather than theoretical. Iboga, peyote, and ayahuasca all carry documented traditional use and growing commercial interest, and the organisations here are where the legal and ethical machinery for handling that intersection actually lives.
- Organisations
- 15
- Countries
- 2
Specific Groups
By country
All Organisations
ABS Capacity Development Initiative
Multi-donor implementation initiative (managed by GIZ) supporting national ABS frameworks, equitable value chains, and ABS-compliant partnerships.
Access and Benefit-sharing Clearing-House (ABSCH)
Global information platform established under the Nagoya Protocol for ABS legislation, national focal point and competent authority listings, and implementation records.
Blessings of the Forest
Gabon/UK social organization focused on iboga conservation, anti-biopiracy, and implementation of Nagoya-aligned legal export and benefit-sharing models connected to Bwiti traditional knowledge holders.
CBD Secretariat (Nagoya Protocol)
UN Convention on Biological Diversity secretariat supporting implementation of the Nagoya Protocol and coordinating ABS policy, compliance processes, and party information exchange.
Ebyeng Edzuameniene Association (A2E)
Community forest management association in Gabon presented as a pilot iboga plantation and Nagoya Protocol implementation project, including benefit-sharing and local income-generation initiatives.
FairWild Foundation
Non-profit standard-setting and assurance organization for sustainable and fair wild-harvest value chains, with explicit documentation of ABS intersections.
Federal Agency for Nature Conservation (BfN)
German federal authority serving as a competent national authority contact for Nagoya Protocol implementation functions and ABS coordination in Germany.
Filament Health
Filament Health is a Canadian natural-psychedelics drug-development company and a leading supplier of pharmaceutical-grade botanical psilocybin. Its patented lead candidate, PEX010, is a standardised natural psilocybin drug candidate used across more than 80 academic and clinical studies worldwide, including Germany's compassionate-use programme and numerous depression, PTSD and cancer-distress trials. On 30 April 2026, Filament was acquired by and became a wholly-owned subsidiary of Red Light Holland (Cboe CA: TRIP), which now advances the PEX010 supply business and a patent portfolio of 76 issued patents across 15 families. In July 2026 Filament agreed to supply PEX010 for an ARQ National Psychotrauma Centre veterans-PTSD study in the Netherlands.
Indigenous Medicine Conservation Fund (IMC Fund)
Conservation and reciprocity fund supporting Indigenous and local communities in medicine-plant stewardship, including iboga and peyote-related biocultural initiatives.
Indigenous Peyote Conservation Initiative (IPCI)
Indigenous-led conservation initiative focused on peyote habitat protection, Native church support, and long-term stewardship of culturally significant medicine plants.
Natural Justice
African legal and rights organization supporting communities on ABS implementation, biocultural community protocols, and Indigenous/traditional knowledge stewardship.
Office for Product Safety and Standards (OPSS)
UK enforcement body appointed by Defra to enforce Nagoya Protocol ABS compliance regulations for users of genetic resources and associated traditional knowledge.
Reconnect Foundation
Reconnect Foundation is a Swiss charitable organization that operates from Switzerland and supports work at the intersection of consciousness research, healthcare accessibility, and ecosystem conservation. Its public materials describe an emphasis on open science, support for academic research, and collaboration with Indigenous Peoples and local communities. It also says the foundation was established by the founders of Reconnect Labs, a Swiss biotech company based at the University of Zurich. In psychedelic-adjacent work, Reconnect Foundation says it supports consciousness research using psychedelics and other consciousness-altering methods, along with mindfulness and ethnobotanical research into ancestral practices. It also runs a benefit-sharing and ecosystem restoration effort focused on Indigenous rights, biocultural conservation, and consultation with Indigenous leaders and partner NGOs in the Amazon region. Documented collaborators named on its site include the Indigenous Medicine Conservation Fund, ICEERS, and El Puente.
Terragnosis
Canadian drug development company active in iboga/ibogaine sourcing and extraction, with public claims of Nagoya-compliant supply and reciprocal benefit-sharing structures in Gabon.
Union for Ethical BioTrade (UEBT)
Non-profit standards and assurance organization supporting ethical sourcing, due diligence, and benefit-sharing approaches for biodiversity-based ingredient value chains.
Frequently asked questions
- What is access and benefit-sharing (ABS)?
The international framework, formalised in the Nagoya Protocol under the Convention on Biological Diversity, requiring that access to genetic resources and associated traditional knowledge happens with consent and that benefits flow back to the communities and countries providing them. For psychedelic compounds derived from traditional plants, it is the closest thing to binding rules the field has.
- Does ABS law apply to psychedelic drug development?
Often yes, and companies discover this late. Developing compounds from iboga sourced in Gabon, for instance, triggers ABS obligations that at least one psychedelic company has formally engaged with. Synthetic routes complicate but do not automatically erase the questions around traditional knowledge. The compliance bodies tracked here are where obligations get assessed.
- Who checks that benefit-sharing actually happens?
A mix tracked across the L3 groups here: national authorities and focal points administer the legal side, third-party auditors and traceability systems verify supply chains, and civil-society organisations (the ethical-trade group) apply public pressure where formal enforcement is weak, which it often is.